- Functional Neuromodulation Ltd.http://www.fxneuromod.com
Functional Neuromodulation Ltd. is a start-up medical technology company focused on advancing innovative neuromodulation technologies for the treatment of cognitive and memory disorders.
- gIcare Pharma Inchttp://www.gicarepharma.com
gIcare Pharma Inc is a biopharmaceutical, start-up company, which develops novel gastrointestinal drugs. Led by a dynamic management highly experienced in gastroenterology, the Company's intent is to develop innovative medicines which align with currently unmet medical needs.
Impopharma Inc. is a pharmaceutical company focused on the development of nasal and pulmonary products.
- Invitae Corporationhttp://invitae.com
Invitae Corporation is a company focused on commercial applications of next generation sequencing. The company is applying advances in genomics to provide more comprehensive, less costly, higher quality clinical genetic solutions for patient, providers and payer alike.
- Naurex Inc.http://www.naurex.com
Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR).
- Profound Medical Inc.http://www.profoundmedical.com
Profound Medical Inc., founded in June 2008, is a privately-held medical device company dedicated to developing a novel treatment for Prostate Cancer; delivering the fastest, least-invasive, and highest Quality-of-Life outcomes for patients of the disease.
- Therapeutic Monitoring Systemshttp://www.therapeuticmonitoring.com
Therapeutic Monitoring Systems is a software development company. Its CIMVA software platform holds the promise of greatly enhancing patient care while saving the healthcare system significant costs associated with clinical uncertainty.
- Tioga Pharmaceuticals, Inc.http://www.tiogapharma.com/
Tioga Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of pruritus. Tioga's lead compound, asimadoline, is in a Phase 2 study in patients with pruritus due to atopic dermatitis.